IN BRIEF: Haleon sets historical results under new reporting structure

Haleon PLC - Surrey, England-based consumer healthcare products - Provides a historical earnings breakdown based its new reporting structure ahead of interim results on July 31. Haleon at a capital markets day back in May said it would start to report in six product categories: Oral Health, Vitamins, Minerals & Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health & Other. This splits out Respiratory Health and Therapeutic Skin Health & Other from what had been Digestive Health & Other. Within Haleon’s £11.23 billion in total revenue in 2024, Oral Health, which includes the Sensodyne brand, was the biggest of these segments at £3.31 billion, followed by Pain Relief, with the Advil and Panadol brands, at £2.56 billion. Haleon says its geographic split remain unchanged.

Current stock price: 376.70 pence, down 0.3% on Monday morning in London

12-month change: up 15%

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.